US5631365A
(en)
*
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5886171A
(en)
*
|
1996-05-31 |
1999-03-23 |
Schering Corporation |
3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
|
US6207822B1
(en)
|
1998-12-07 |
2001-03-27 |
Schering Corporation |
Process for the synthesis of azetidinones
|
WO2000034240A1
(en)
*
|
1998-12-07 |
2000-06-15 |
Schering Corporation |
Process for the synthesis of azetidinones
|
AU1609702A
(en)
*
|
2000-12-21 |
2002-07-01 |
Aventis Pharma Gmbh |
Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
|
DK1353696T3
(da)
*
|
2001-01-26 |
2007-04-10 |
Schering Corp |
Kombinationer af peroxisomproliferatoraktiveret receptor (PPAR)-aktivator(er) og sterolabsorptionsinhibitor(er) og behandlinger til vaskulære indikationer
|
US20060287254A1
(en)
*
|
2001-01-26 |
2006-12-21 |
Schering Corporation |
Use of substituted azetidinone compounds for the treatment of sitosterolemia
|
RS50386B
(sr)
|
2001-03-28 |
2009-12-31 |
Schering Corporation, |
Enantioselektivna sinteza intermedijarnih jedinjenja azetidinona
|
EP1429756B1
(de)
*
|
2001-09-21 |
2006-11-22 |
Schering Corporation |
Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
|
US20030204096A1
(en)
*
|
2002-03-25 |
2003-10-30 |
Schering Corporation |
Enantioselective synthesis of azetidinone intermediate compounds
|
US7176194B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
US7176193B2
(en)
|
2002-06-19 |
2007-02-13 |
Sanofi-Aventis Deutschland Gmbh |
Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
US7671047B2
(en)
|
2002-06-19 |
2010-03-02 |
Sanofi-Aventis Deutschland Gmbh |
Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
|
GB0215579D0
(en)
*
|
2002-07-05 |
2002-08-14 |
Astrazeneca Ab |
Chemical compounds
|
US7135556B2
(en)
*
|
2002-07-19 |
2006-11-14 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
EP1601668B1
(de)
*
|
2003-03-07 |
2008-08-27 |
Schering Corporation |
Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
|
US7459442B2
(en)
*
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
ES2318274T3
(es)
*
|
2003-03-07 |
2009-05-01 |
Schering Corporation |
Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
|
AR041089A1
(es)
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
|
WO2005009955A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Hetero Drugs Limited |
Ezetimibe polymorphs
|
US7067675B2
(en)
|
2003-11-24 |
2006-06-27 |
Hetero Drugs Limited |
Process for ezetimibe intermediate
|
WO2005061452A1
(en)
*
|
2003-12-23 |
2005-07-07 |
Astrazeneca Ab |
Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
|
GB0329778D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Astrazeneca Ab |
Chemical compounds
|
US7901893B2
(en)
*
|
2004-01-16 |
2011-03-08 |
Merck Sharp & Dohme Corp. |
NPC1L1 (NPC3) and methods of identifying ligands thereof
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
US20070244107A1
(en)
*
|
2004-08-25 |
2007-10-18 |
Waters M Gerard |
Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
|
WO2006060808A1
(en)
*
|
2004-12-03 |
2006-06-08 |
Teva Pharmaceutical Industries Ltd. |
Ezetimibe polymorphs
|
US20060234996A1
(en)
*
|
2005-04-14 |
2006-10-19 |
Itai Adin |
Novel crystalline form of ezetimibe and processes for the preparation thereof
|
AU2006262441A1
(en)
*
|
2005-06-20 |
2007-01-04 |
Schering Corporation |
Piperidine derivatives useful as histamine H3 antagonists
|
SA06270191B1
(ar)
*
|
2005-06-22 |
2010-03-29 |
استرازينيكا ايه بي |
مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
|
AR054482A1
(es)
*
|
2005-06-22 |
2007-06-27 |
Astrazeneca Ab |
Derivados de azetidinona para el tratamiento de hiperlipidemias
|
US20070049748A1
(en)
*
|
2005-08-26 |
2007-03-01 |
Uppala Venkata Bhaskara R |
Preparation of ezetimibe
|
KR20070063592A
(ko)
*
|
2005-09-08 |
2007-06-19 |
테바 파마슈티컬 인더스트리즈 리미티드 |
에제티밉의 합성을 위한 중간체인(3r,4s)-4-((4-벤질옥시)페닐)-1-(4-플루오로페닐)-3-((s)-3-(4-플루오로페닐)-3-히드록시프로필)-2-아제티디논의제조 방법
|
RU2008119687A
(ru)
|
2005-10-21 |
2009-11-27 |
Новартис АГ (CH) |
Комбинации органических соединений
|
HUP0501164A2
(en)
*
|
2005-12-20 |
2007-07-30 |
Richter Gedeon Nyrt |
New industrial process for the production of ezetimibe
|
ATE445596T1
(de)
*
|
2005-12-22 |
2009-10-15 |
Medichem Sa |
Verfahren zur herstellung von zwischenprodukten für die herstellung von ezetimibe
|
US7910698B2
(en)
|
2006-02-24 |
2011-03-22 |
Schering Corporation |
NPC1L1 orthologues
|
WO2007108007A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Unichem Laboratories Limited |
A process for the preparation of ezetimibe via a novel intermediate
|
AR060216A1
(es)
*
|
2006-03-29 |
2008-06-04 |
Medichem Sa |
Procesos para preparar ezetimibe y compuestos intermediarios utiles para su preparacion
|
AR060623A1
(es)
*
|
2006-04-27 |
2008-07-02 |
Astrazeneca Ab |
Compuestos derivados de 2-azetidinona y un metodo de preparacion
|
WO2008027081A1
(en)
*
|
2006-08-29 |
2008-03-06 |
Teva Pharmaceutical Industries Ltd. |
Processes for the purification of (3r,4s)-4-(4-hydroxy-protected-phenyl)-1-(4-fluorophenyl)-3-(4-fluorophenyl)-3-oxopropyl] azetidin-2-one
|
US20080103122A1
(en)
*
|
2006-09-05 |
2008-05-01 |
Schering Corporation |
Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
|
WO2008032338A2
(en)
*
|
2006-09-11 |
2008-03-20 |
Manne Satyanarayana Reddy |
Improved process for the preparation of ezetimibe and its intermediates
|
US20100069347A1
(en)
*
|
2006-11-02 |
2010-03-18 |
Morriello Gregori J |
Heterocyclyl-substituted anti-hypercholesterolemic compounds
|
US20090047716A1
(en)
*
|
2007-06-07 |
2009-02-19 |
Nurit Perlman |
Reduction processes for the preparation of ezetimibe
|
US20080319221A1
(en)
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
DE102007054497B3
(de)
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
CZ305066B6
(cs)
*
|
2008-02-25 |
2015-04-22 |
Zentiva, K.S. |
Způsob výroby (3R,4S)-1-(4-fluorfenyl)-3-[(3S)-3-(4-fluorfenyl)-3-hydroxypropyl)]-4-(4-hydroxyfenyl)-2-azetidinonu
|
EP2128133A1
(de)
*
|
2008-05-26 |
2009-12-02 |
Lek Pharmaceuticals D.D. |
Ezetiminverfahren und -zusammensetzung
|
PL387331A1
(pl)
*
|
2009-02-24 |
2010-08-30 |
Instytut Chemii Organicznej Polskiej Akademii Nauk |
Sposób wytwarzania aldehydowego związku beta-laktamowego, związek pośredni, sposób wytwarzania związku pośredniego oraz zastosowanie związku pośredniego
|
WO2010113175A2
(en)
|
2009-04-01 |
2010-10-07 |
Matrix Laboratories Ltd |
Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
|
EP2566497B1
(de)
|
2010-05-04 |
2015-07-29 |
Codexis, Inc. |
Biokatalysatoren zur ezetimib-synthese
|
ES2372460B1
(es)
|
2010-07-09 |
2012-11-16 |
Moehs Ibérica S.L. |
Nuevo método para la preparación de ezetimiba.
|
CN102477008B
(zh)
*
|
2010-11-22 |
2014-05-21 |
沈阳药科大学 |
依泽替米贝的合成方法
|
WO2012076030A1
(en)
*
|
2010-12-10 |
2012-06-14 |
Pharmathen S.A. |
Process for the preparation of intermediate compounds useful in the preparation of ezetimibe
|
WO2012155932A1
(en)
|
2011-05-17 |
2012-11-22 |
Pharmathen S.A. |
Improved process for the preparation of ezetimibe
|
PL231215B1
(pl)
|
2011-06-15 |
2019-02-28 |
Inst Chemii Organicznej Polskiej Akademii Nauk |
Sposób wytwarzania podstawionych azetydynonów oraz związków pośrednich do ich syntezy
|
CN103086938A
(zh)
*
|
2011-10-28 |
2013-05-08 |
沈阳药科大学 |
依泽替米贝的合成方法
|
CN102531986A
(zh)
*
|
2012-02-23 |
2012-07-04 |
苏州朗科生物技术有限公司 |
一种依替米贝的制备方法
|
CN103570574B
(zh)
|
2012-07-20 |
2016-04-13 |
中国科学院上海有机化学研究所 |
一种依泽替米贝的合成方法及该方法中所用的中间体
|
CN103044305A
(zh)
*
|
2013-01-24 |
2013-04-17 |
上海现代制药股份有限公司 |
一种依折麦布中间体的制备方法
|
WO2015039675A1
(en)
|
2013-09-23 |
2015-03-26 |
Pharmathen S.A. |
Novel process for the preparation of ezetimibe intermediates
|
CN103739537B
(zh)
*
|
2013-12-24 |
2015-05-20 |
连云港恒运医药科技有限公司 |
依折麦布的新合成方法
|
CN104072398B
(zh)
*
|
2014-07-03 |
2016-02-03 |
河南省科学院化学研究所有限公司 |
一种合成依折麦布的方法
|
JP2016145173A
(ja)
*
|
2015-02-09 |
2016-08-12 |
株式会社トクヤマ |
(3r,4s)‐1‐(4‐フルオロフェニル)‐[3(s)‐ヒドロキシ‐3‐(4‐フルオロフェニル)プロピル]‐(4‐ヒドロキシフェニル)‐2‐アゼチジノンの製造方法
|
CN107098841A
(zh)
*
|
2016-02-19 |
2017-08-29 |
常州方楠医药技术有限公司 |
一种依折麦布的制备方法及该方法中所用的中间体
|
CN107033051A
(zh)
*
|
2017-06-08 |
2017-08-11 |
武汉励合生物医药科技有限公司 |
一种依泽替米贝的制备方法
|